




Hikal Limited: Highest ever Revenue and Profitability


- Q4 Revenue Rs. 290 Crores
- Q4 Net Profit of Rs. 22 Crores
- Final Dividend of Re. 1 per share (50% of Face value)

Mumbai, May 6, 2016: Hikal Ltd, a preferred long-term partner for leading global life sciences companies, announced its financial results for the financial year ended 31st March 2016.


Performance highlights for the quarter ended 31st March 2016



- **Net sales up 36% to Rs. 290 crores** as compared to Rs. 214 crores in the corresponding period of the previous year.
- **EBITDA was up 32% to Rs. 60 crores** as compared to Rs. 45 crores in the corresponding period of the previous year.
- **Pharmaceutical sales were up by 22% to Rs. 169 crores** as compared to Rs. 139 crores in the corresponding period of the previous year.
- **Crop protection sales were up by 62% to Rs. 121 crores** as compared to Rs. 75 crores in the corresponding period of the previous year.
- **Net Profit was up by 118% at Rs. 22 crores** as compared to Rs. 10 crores in the corresponding period of the previous year.

**Performance highlights for the Half Year ended 31st March 2016**

- **Net sales up 21% to Rs. 530 crores** as compared to Rs. 439 crores in the corresponding period of the previous year.
- **EBITDA was up 14% to Rs. 106 crores** as compared to Rs. 93 crores in the corresponding period of the previous year.
- **Pharmaceutical sales were up by 11% to Rs. 307 crores** as compared to Rs. 276 crores in the corresponding period of the previous year.
- **Crop protection sales were up by 36% to Rs. 222 crores** as compared to Rs. 163 crores in the corresponding period of the previous year.
- **Net Profit was up by 70% at Rs. 34 crores** as compared to Rs. 20 crores in the corresponding period of the previous year.

**Performance highlights for the Year ended 31st March 2016**

- **Net sales up by 6% to Rs. 926 crores** as compared to Rs. 872 crores in the corresponding period of the previous year.
- **Pharmaceutical sales up by 6% to Rs. 569 crores** as compared to Rs. 538 crores in the corresponding period of the previous year.
- **Crop protection sales up by 7% to Rs. 356 crores** as compared to Rs. 334 crores in the corresponding period of the previous year.
- **EBITDA was Rs. 181 crores** as compared to Rs. 182 crores in the corresponding period of the previous year.
- **Net Profit was up 2% to Rs. 41 crores** as compared to Rs. 41 crores.



Commenting on the results, Jai Hiremath, Chairman & Managing Director, Hikal Ltd. said, “We are pleased to announce that the Board have declared 25% as an interim dividend and recommended a Final Dividend of 25% subject to shareholders approval which would make the total dividend for the year to 50%.

In the last year we have focused on increasing the business for both the divisions and strengthening our balance sheet. We have expanded our team by adding more professionals with expertise in both our business divisions. We have also added more new products in both the divisions. The results of the same will be visible in the years to come.

Our last quarter results have shown record performance with Sales of Rs. 290 cr; an increase of 36%. Our EBITDA margins and profits have improved by 32% and 118% respectively. We had an excellent quarter in both our pharmaceutical and crop protection divisions where revenues were up by 22% in pharma and 62% in crop protection.

For the year, 2015-2016 our revenues were up by 6% to 926 cr. Both the divisions have done well registering a growth of 6% in Pharmaceuticals Sales and 7% for Crop Protection Sales. Our Net Profit for the year was up by 2% to 41 cr compared to previous year.

Our strategy to diversify our customer and market base has aided the positive results this financial year. We have introduced new products in both divisions. We expect growth and profitability to continue into years ahead.”

About Hikal Limited:

Hikal is a reliable long-term partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates, manufactured using stringent global quality standards, for its global customers. Hikal’s advanced manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja and Mahad (Maharashtra). Hikal’s R&D facilities are located at Pune. The Pharmaceutical manufacturing facilities are situated in Jigani (Bangalore) and Panoli (Gujarat).

Safe harbor Statement:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Hikal Ltd. – **Anish Swadi** +91-22-3097 3100, Email – anish_swadi@hikal.com

Strategic Growth Advisors Pvt. Ltd. - **Payal Dave**+91 22 6114 6679 – dpayal@sgapl.net

HIKAL LTD

4

Admin Office: Great Eastern Chambers, CBD Belapur, Navi Mumbai – 400614 Tel : (91-22) 30973100 Fax : (91-22) 27574227 E-mail: info@hikal.com

Regd Office: 717/718, 7th Floor, Maker Chambers V, Nariman Point, Mumbai – 400021 Tel : (91-22) 66301801 Fax : (91-22) 22833913

CIN: L24200MH1988PTC048028